secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001213900-26-053075
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics Q1 net loss $2.5M; details Phase 3 plan for CAD-1005 in HIT
--------------------------------------------------------------------------------

- Net loss $2.5M in Q1 2026 vs $3.8M in Q1 2025; operating expenses $2.5M vs $3.9M.
- Cash $2.3M at March 31; subsequent $2.5M financing completed April 1, 2026.
- Received FDA EOP2 meeting minutes; plans randomized, blinded, placebo-controlled Phase 3 trial in ~120 HIT patients.
- Phase 2 data showed >25% absolute reduction in thrombotic events with CAD-1005 added to standard anticoagulant therapy.
- CAD-1005 is first-in-class 12-LOX inhibitor; holds FDA Orphan Drug and Fast Track designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026053075/0001213900-26-053075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026053075/ea0289377-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-053075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer